TU2218 Clinical Trials (2026): 2 Studies for Advanced Solid Tumor & Biliary Tract Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 TU2218 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Advanced Solid Tumor & Biliary Tract Cancer) and 380 total planned enrollment. 2 TU2218 clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT05784688 (Dec 2028).
Where to Participate: All TU2218 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting TU2218trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | NEXT Oncology | San Antonio78229 | NCT05204862 | Map |
TU2218 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 2 | 2 |
Recruiting TU2218 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | P1/P2 | Solid Tumor | 140 | Mar 2023 |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumor | 240 | Dec 2021 |
TU2218 clinical trials by indication
Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05784688 | — | P1/P2 | recruiting | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05204862 | — | P1/P2 | recruiting | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors |
All TU2218 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 140 | TiumBio Co., Ltd. | Mar 2023 | |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 240 | TiumBio Co., Ltd. | Dec 2021 |
TU2218 clinical trials: frequently asked questions
- How many TU2218 clinical trials are there?
- 2 TU2218 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are TU2218 clinical trials recruiting in 2026?
- Yes — 2 TU2218 trials are actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is TU2218 being studied for?
- TU2218 is being studied for Advanced Solid Tumor, Biliary Tract Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumor. The trials are grouped by indication on this page.
- Who sponsors TU2218 clinical trials?
- The lead sponsor across the most TU2218 trials is TiumBio Co., Ltd.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming TU2218as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: